title: A randomized clinical trial comparing granulocyte-colony-stimulating factor administration sites for mobilization of peripheral blood stem cells for patients with hematologic malignancies undergoing autologous stem cell transplantation.
abstract: BACKGROUND
  A study was undertaken to investigate whether granulocyte-colony-stimulating factor (G-CSF) injection in lower adipose tissue-containing sites (arms and legs) would result in a lower exposure and reduced stem cell collection efficiency compared with injection into abdominal skin.
  
  
  METHODS
  We completed a prospective randomized study to determine the efficacy and tolerability of different injection sites for patients with multiple myeloma or lymphoma undergoing stem cell mobilization and apheresis. Primary endpoints were the number of CD34+ cells collected and the number of days of apheresis. Forty patients were randomly assigned to receive cytokine injections in their abdomen (Group A) or extremities (Group B). Randomization was stratified based on diagnosis (myeloma, n=29 vs. lymphoma, n=11), age, and mobilization strategy and balanced across demographic factors and body mass index.
  
  
  RESULTS
  Thirty-five subjects were evaluable for the primary endpoint: 18 in Group A and 17 in Group B. One evaluable subject in each group failed to collect a minimum dose of at least 2.0×10(6) CD34+ cells/kg. The mean numbers of CD34+ cells (±SD) collected were not different between Groups A and B (9.15×10(6)±4.7×10(6) /kg vs. 9.85×10(6) ±5×10(6) /kg, respectively; p=NS) after a median of 2 days of apheresis. Adverse events were not different between the two groups.
  
  
  CONCLUSIONS
  The site of G-CSF administration does not affect the number of CD34+ cells collected by apheresis or the duration of apheresis needed to reach the target cell dose.
authors.affiliation: Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA.
authors.forename: Heather
authors.initials: H
authors.lastname: Renfroe
authors.forename: Mike
authors.initials: M
authors.lastname: Arnold
authors.forename: Louette
authors.initials: L
authors.lastname: Vaughn
authors.forename: R Donald
authors.initials: RD
authors.lastname: Harvey
authors.forename: Ellie
authors.initials: E
authors.lastname: Hamilton
authors.forename: Sagar
authors.initials: S
authors.lastname: Lonial
authors.forename: H Jean
authors.initials: HJ
authors.lastname: Khoury
authors.forename: Jonathan L
authors.initials: JL
authors.lastname: Kaufman
authors.forename: Mary Jo
authors.initials: MJ
authors.lastname: Lechowicz
authors.forename: Christopher R
authors.initials: CR
authors.lastname: Flowers
authors.forename: Edmund K
authors.initials: EK
authors.lastname: Waller
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D004333:Drug Administration Routes; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D019337:Hematologic Neoplasms / Q000628:therapy*; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D006801:Humans; D008223:Lymphoma / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000628:therapy; D036102:Peripheral Blood Stem Cell Transplantation / Q000379:methods*; D011994:Recombinant Proteins; D014182:Transplantation, Autologous; D055815:Young Adult
chemical_list: D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor